Tagline staff members Tara Rabin, Sandy Dean and Jim McKinney returned to the FDA campus for a public hearing on the Commissioner’s National Priority Voucher (CNPV) pilot program.
We heard from supporters of the program, people with ideas for improving it and rare disease advocates who reminded us whom we serve through our public health work.
“One company called the program the ‘magic wand.’”
As with any pilot, opinions differed. Speakers from companies who received vouchers were enthusiastic. One called the program a “magic wand,” while another praised the process for maintaining rigorous review standards.
Several common recommendations for improving the pilot emerged:
- Clearer eligibility criteria, greater transparency and more predictable processes for selecting products and awarding vouchers;
- Further evaluation of whether expedited review pathways are associated with increased post-approval safety signals;
- Concerns that the CNPV pilot program may overlap with expedited programs established by Congress while lacking its own statutory framework and formal guidance;
- Selection criteria that remain focused on the FDA’s public health mission and avoid considerations outside the agency’s purview, such as drug pricing.
- Concern that the pilot could draw from already limited resources and affect reviews of other important therapies.
The docket closed June 29; now the FDA is reviewing nearly 600 submitted comments. Tagline will continue to watch to see if this pilot is here to stay or a moment in time.
What do you think the future holds for the CNPV program? Share your perspective here.

